David J. Arthur - Feb 13, 2023 Form 4 Insider Report for Salarius Pharmaceuticals, Inc. (SLRX)

Role
Chief Executive Officer, Director
Signature
/s/Mark Rosenblum, as Attorney-in-Fact
Stock symbol
SLRX
Transactions as of
Feb 13, 2023
Transactions value $
$0
Form type
4
Date filed
2/15/2023, 03:04 PM
Previous filing
Jan 5, 2023
Next filing
Apr 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLRX Common Stock Award $0 +14.3K +42.41% $0.00 48K Feb 13, 2023 Direct F1
holding SLRX Common Stock 564 Feb 13, 2023 By son
holding SLRX Common Stock 552 Feb 13, 2023 By daughter
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock granted under the Salarius Pharmaceuticals, Inc. 2015 Equity Incentive Plan in lieu of cash for performance bonus. The shares of common stock are subject to a six-month holding period pursuant to the terms of the restricted stock agreement.